Project description
Dermatological cream for the topical treatment of skin ulcers
Acute and chronic skin ulcers, such as diabetic foot ulcers, pressure ulcers and leg ulcers, dramatically decrease the quality of life in affected patients, and currently available therapeutic procedures have low efficacy. The EU-funded LYSADERM project aims to develop the first medicinal cream containing platelet lysate (PL) that can be used for the topical therapy of skin ulcers. Platelets have demonstrated their potential in enhancing the healing of skin, muscles, tendons and ligaments as the growth factors released by platelets recruit reparative cells. Phase I of the project will evaluate the technical feasibility and economic viability of the product development.
Objective
The LYSADERM project aims at the fabrication of a medicinal cream containing Platelet Lysate (PL), that can be used for the topical therapy of skin ulcers. The applicant company Episkey is an innovative start-up founded in 2016 with the aim of introducing into the market novel therapeutic products obtained from human Platelet Lysate. Episkey holds the exclusive licenses of international patents covering the therapeutic administration of cord blood Platelet Lysate, and already developed an international network of cord blood banks aimed at the procurement of Cord Blood Platelet Lysate for pharmaceutical transformation into platelet derivatives and drugs. Within the broad scope of our company mission, the LYSADERM project aims at marketing a novel formulation of dermatological cream containing tissue regenerative factors present in human platelets. The LYSADERM dermatological cream will be therefore used for the treatment of skin ulcers, including serious disorders, such as diabetic foot ulcers, pressure ulcers and leg ulcers. LYSADERM aims to be the first pharmaceutical cream containing Platelet Lysate, and it is expected to improve healing of the ulcers in comparison to conventional treatments, at lower cost; therefore, it would become the standard procedure to treat diabetic foot ulcers, pressure ulcers and leg ulcers. The LYSADERM business project is expected to generate positive outcomes for the whole society, such as the increase of effectiveness in the treatment of skin ulcers both in hospitals and at the patient’s home. It is roughly estimated that once industrialized, LYSADERM can generate in just 5 years a total of over 10 M annual revenues, covering the 0.4% of the EU market share. Overall, the main objective of our phase I project is to achieve the technical definition of the LYSADERM product, to realize a complete exploitation plan, and to consolidate our business plan through a second-level FTO and the definition of the financial forecasts.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineendocrinologydiabetes
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesmedical biotechnologycells technologiesstem cells
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
20121 MILANO
Italy
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.